Abstract Recently, United States Food and Drug Administration (FDA) and European
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …

Due to a series of systemic and intracellular obstacles in nucleic acid (NA) therapy, including
fast degradation in blood, renal clearance, poor cellular uptake, and inefficient endosomal …

Cancer progression to metastatic stages is still unmanageable and the promise of effective
anti-metastatic therapy remains largely unmet, emphasizing the need to develop novel …

Human hepatocellular carcinoma (HCC) has been recognized as one of the significant
causes of mortality around the globe. In recent years, extensive research has been carried …

Synthetic vectors for therapeutic nucleic acid delivery are currently competing significantly
with their viral counter parts due to their reduced immunogenicity, large payload capacity …

Circular RNAs (circRNAs) are a class of highly stable and closed-loop noncoding RNA that
are involved in the occurrence and development of hepatocellular carcinoma (HCC) …

Tumor microenvironment is known to play important roles in tumor progression. Many
therapies, targeting the tumor microenvironment, are designed and applied in the clinic. One …

The EWS/FLI1 fusion gene is well characterized as a driver of Ewing's sarcoma. Bi-shRNA
EWS/FLI1 is a functional plasmid DNA construct that transcribes both siRNA and miRNA-like …

Osteosarcoma (OS) is one of the most prevalent and highly aggressive bone malignancies.
The treatment strategies of OS is under standard regimens, including surgical resection …

Abstract MicroRNA-34a (miR-34a) is a master regulator of signaling networks that maintains
normal physiology and disease and is currently in development as a miRNA-based therapy …